NASDAQ:FULC

Fulcrum Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy FULC

*Your capital is at risk

$3.58

-0.140 (-3.76%)

At Close: Jul 31, 2026

Fulcrum Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -83.25. In total, the insiders bought 40.84M and sold 21.27M FULC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-83.25
● Buy	40.84M shares
● Sell	21.27M shares
83% Buy Activity Weak Negative Correlation
Buy Signal Low Confidence Jul 16, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -83.25. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (83% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 15, 2025 Sell	Common Stock S-Sale	Oltmans Curtis Gale Chief Legal Officer	Officer	3 452 Value: $44.6K
Dec 08, 2025 Sell	Common Stock S-Sale	Ra Capital Management, L.p. 10 Percent Owner	10% Owner	1 377 020 Value: $18.4M
Dec 08, 2025 Sell	Common Stock S-Sale	Ra Capital Management, L.p. 10 Percent Owner	10% Owner	2 706 397 Value: $38.6M
Dec 08, 2025 Sell	Common Stock S-Sale	Ra Capital Management, L.p. 10 Percent Owner	10% Owner	91 722 Value: $1.37M
Nov 19, 2025 Sell	Common Stock S-Sale	Gould Robert J Director	Director	15 000 Value: $165.5K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Geraghty James A Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Dorton Katina Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Haviland Kate Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Hill Colin Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	King Rachel K. Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Banks Sonja Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Gould Robert J Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Ezekowitz Alan Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Ezekowitz Alan Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Gould Robert J Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Banks Sonja Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	King Rachel K. Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Hill Colin Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Haviland Kate Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Dorton Katina Director	Director	36 000 Value: $265.7K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Geraghty James A Director	Director	36 000 Value: $265.7K
May 08, 2025 Sell	Common Stock S-Sale	Tourangeau Greg Principal Accounting Officer	Officer	498 Value: $3K
May 08, 2025 Sell	Common Stock S-Sale	Tourangeau Greg Principal Accounting Officer	Officer	498 Value: $3K
Jan 24, 2025 Buy	Stock Option (right to buy) A-Award	Musso Alan A Chief Financial Officer	C-Suite Officer	285 000 Value: $1.19M
Jan 24, 2025 Buy	Stock option - Right to Buy A-Award	Sapir Alex See Remarks	Officer	582 000 Value: $2.42M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT FULCRUM THERAPEUTICS, INC.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell di...

Read Full Profile Here